^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ROS1 mutation

    i
    Other names: ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1
    Entrez ID:
    6098
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative (NCT04929041)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    10/07/2022
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    EGFR • PD-L1 • ALK • ROS1
    |
    PD-L1 expression • ALK mutation • ROS1 mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)
    Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PIKACHU) (NCT04322890)
    Phase 2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/16/2020
    Primary completion :
    12/24/2026
    Completion :
    12/24/2027
    EGFR • BRAF • ALK • ROS1
    |
    EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation
    |
    cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)
    Genetic Testing in Guiding Treatment for Patients With Brain Metastases (NCT03994796)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    08/15/2019
    Primary completion :
    10/01/2024
    Completion :
    06/01/2025
    KRAS • BRAF • ER • PGR • ROS1 • NTRK
    |
    HER-2 positive • EGFR mutation • HER-2 negative • ROS1 mutation • BRAF positive
    |
    Rozlytrek (entrectinib) • Verzenio (abemaciclib) • Krazati (adagrasib) • paxalisib (GDC-0084)
    NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60) (NCT04332653)
    Phase 1/2
    NeoImmuneTech
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    06/10/2020
    Primary completion :
    11/05/2024
    Completion :
    03/31/2025
    BRAF • ALK • ROS1
    |
    EGFR mutation • BRAF mutation • ALK translocation • ROS1 mutation
    |
    Keytruda (pembrolizumab) • Hyleukin-7 (efineptakin alfa)
    Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors (NCT05757492)
    Phase 1/2
    Coherus Biosciences, Inc.
    Active, not recruiting
    Last update posted :
    02/20/2024
    Initiation :
    04/26/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR • PD-L1 • ALK • MET • ROS1
    |
    EGFR mutation • ALK mutation • MET mutation • ROS1 mutation
    |
    Loqtorzi (toripalimab-tpzi) • JS006
    PBF-1129 in Patients With NSCLC (NCT03274479)
    Phase 1
    Palobiofarma SL
    Active, not recruiting
    Last update posted :
    02/09/2024
    Initiation :
    10/01/2018
    Primary completion :
    05/01/2024
    Completion :
    08/01/2024
    EGFR • ALK • ROS1
    |
    ALK mutation • ROS1 mutation
    |
    PBF-1129
    CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer (NCT02955290)
    Phase 1/2
    Roswell Park Cancer Institute
    Recruiting
    Last update posted :
    11/08/2023
    Initiation :
    12/22/2016
    Primary completion :
    12/09/2027
    Completion :
    12/09/2027
    PD-L1 • KRAS • ALK • ROS1
    |
    PD-L1 expression • ALK mutation • ROS1 mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • CimaVax EGF (EGF-PTI)
    Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    11/03/2023
    Initiation :
    04/04/2016
    Primary completion :
    10/04/2023
    Completion :
    10/11/2024
    PD-L1 • BRAF • ALK • ROS1 • CD4
    |
    BRAF V600 • ALK mutation • ROS1 mutation
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 (NCT02426658)
    Phase 2
    Wake Forest University Health Sciences
    Completed
    Last update posted :
    10/12/2023
    Initiation :
    05/01/2015
    Primary completion :
    04/19/2018
    Completion :
    10/07/2022
    EGFR • ALK • ROS1
    |
    ROS1 mutation
    |
    pemetrexed
    A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors (NCT06055166)
    Phase 2
    Chongqing University Cancer Hospital
    Not yet recruiting
    Last update posted :
    09/26/2023
    Initiation :
    11/01/2023
    Primary completion :
    11/30/2024
    Completion :
    05/31/2026
    EGFR • ALK • ROS1
    |
    EGFR mutation • ALK mutation • ROS1 mutation
    |
    AiRuiKa (camrelizumab) • capecitabine • AiRuiYi (fluzoparib)
    A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT03952403)
    Phase 3
    Shanghai Henlius Biotech
    Active, not recruiting
    Last update posted :
    08/08/2023
    Initiation :
    12/02/2019
    Primary completion :
    10/01/2023
    Completion :
    03/15/2024
    PD-L1 • ALK • TMB • MSI • ROS1
    |
    PD-L1 expression • ALK mutation • ROS1 mutation
    |
    carboplatin • pemetrexed • Hetronifly (serplulimab) • Hanbeitai (bevacizumab biosimilar)
    A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy (LIST) (NCT04500535)
    Phase N/A
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    05/22/2023
    Initiation :
    09/28/2020
    Primary completion :
    09/15/2025
    Completion :
    09/15/2025
    EGFR • HER-2 • PD-L1 • KRAS • BRAF • ALK • MET • ROS1
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • BRAF mutation • MET mutation • ALK translocation • ROS1 mutation
    |
    Opdivo (nivolumab)
    Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors (NCT05645315)
    Phase 1/2
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    12/09/2022
    Initiation :
    04/28/2022
    Primary completion :
    12/01/2023
    Completion :
    06/01/2024
    EGFR • ALK • ROS1 • HAVCR2
    |
    PD-L1 expression • ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation
    |
    Andewei (benmelstobart) • TQB2618
    Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC (NCT03164772)
    Phase 1/2
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/10/2022
    Initiation :
    12/20/2017
    Primary completion :
    10/29/2021
    Completion :
    10/29/2021
    EGFR • ALK • ROS1
    |
    EGFR mutation • ALK mutation • ROS1 mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • BI 1361849 • self-amplifying RNA cancer vaccine
    Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged (NCT05116618)
    Phase N/A
    University of Colorado, Denver
    Withdrawn
    Last update posted :
    09/21/2022
    Initiation :
    01/06/2022
    Primary completion :
    09/15/2022
    Completion :
    09/15/2022
    EGFR • ALK • ROS1
    |
    EGFR mutation • ALK rearrangement • ALK mutation • ROS1 rearrangement • ROS1 mutation • ALK amplification
    Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers (NCT03868423)
    Phase 2
    Sameek Roychowdhury
    Withdrawn
    Last update posted :
    02/18/2022
    Initiation :
    03/20/2019
    Primary completion :
    11/20/2020
    Completion :
    12/30/2021
    ALK • ROS1
    |
    ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation
    |
    Alunbrig (brigatinib)
    Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC (NCT05055583)
    Phase 2
    Tang-Du Hospital
    Recruiting
    Last update posted :
    09/24/2021
    Initiation :
    08/31/2021
    Primary completion :
    08/31/2023
    Completion :
    12/31/2023
    EGFR • ALK • ROS1
    |
    EGFR mutation • ALK mutation • ALK wild-type • ROS1 mutation • ROS1 wild-type
    |
    cisplatin • carboplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC (NCT04846452)
    Phase 2
    The First Affiliated Hospital with Nanjing Medi...
    Recruiting
    Last update posted :
    08/12/2021
    Initiation :
    06/01/2021
    Primary completion :
    05/01/2023
    Completion :
    05/01/2023
    ALK • ROS1
    |
    ALK mutation • ROS1 mutation
    |
    cisplatin • carboplatin • paclitaxel • Focus V (anlotinib) • Tyvyt (sintilimab) • albumin-bound paclitaxel • pemetrexed
    A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment (SNK_ASTER) (NCT04872634)
    Phase 1/2
    NKMAX Co., Ltd.
    Recruiting
    Last update posted :
    07/21/2021
    Initiation :
    07/08/2021
    Primary completion :
    05/26/2023
    Completion :
    05/26/2023
    EGFR • ALK • ROS1
    |
    EGFR mutation • ALK mutation • ROS1 mutation
    |
    Erbitux (cetuximab) • carboplatin • gemcitabine • troculeucel (SNK01)
    Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC (NCT03636685)
    Phase 1/2
    Chinese Academy of Medical Sciences
    Unknown status
    Last update posted :
    08/17/2018
    Initiation :
    08/15/2018
    Primary completion :
    08/14/2019
    Completion :
    08/14/2020
    EGFR • ALK • ROS1
    |
    EGFR mutation • ALK mutation • ALK wild-type • ROS1 mutation • ROS1 wild-type
    |
    carboplatin • paclitaxel • Focus V (anlotinib) • pemetrexed
    ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC (NCT02946216)
    Phase N/A
    First People's Hospital of Hangzhou
    Unknown status
    Last update posted :
    10/27/2016
    Initiation :
    11/01/2016
    Primary completion :
    11/01/2017
    Completion :
    11/01/2018
    EGFR • ALK • MET • ROS1
    |
    EGFR wild-type • ALK mutation • MET mutation • ROS1 mutation